GlassScriptPhysician profile
Julia A Buesser
NPI 1013390491
$18,375.08
in general payments reported to CMS, 2019-2025
41 companies · $1,254 in 2025
The $1,254 reported for 2025 was more than what 88% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,175 · 2022: $8,911 · 2023: $2,758 · 2024: $1,277 · 2025: $1,254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,912 · Travel and Lodging: $1,293 · Consulting Fee: $995 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,912.13 |
| Travel and Lodging | $1,293.26 |
| Consulting Fee | $995.00 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $11,422.47 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $2,570.98 | 2023-2025 | Gemtesa |
| Abbvie INC. | $987.53 | 2021-2025 | |
| Janssen Biotech, INC. | $395.67 | 2021-2025 | Erleada, Akeega, Balversa |
| Rochester Medical Corporation | $337.18 | 2021-2022 | |
| Astellas Pharma US INC | $322.80 | 2021-2025 | Myrbetriq, Xtandi |
| Merck Sharp & Dohme LLC | $268.85 | 2021-2024 | Keytruda, Lynparza, Welireg |
| Olympus America INC. | $193.67 | 2022-2025 | Itind System, Cysto-Nephro Videoscope |
| Boston Scientific Corporation | $172.77 | 2025 | Ams 700, Ams 800 Artificial Urinary Sphincter |
| Antares Pharma, INC. | $161.77 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Progenics Pharmaceuticals, INC. | $139.68 | 2021-2023 | Pylarify |
| Pacira Pharmaceuticals Incorporated | $117.78 | 2024-2025 | Exparel |
| Dendreon Pharmaceuticals LLC | $114.39 | 2022-2025 | Provenge |
| Immunitybio, INC. | $110.44 | 2024-2025 | |
| Smith+Nephew, INC. | $106.91 | 2025 | Stravix Pl, Grafix Pl |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Buesser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.